Levothyroxine therapy – factors influencing its outcome

Czech version

Authors: Marcela Dvořáková
Authors‘ workplace: Endokrinologický ústav, Praha
Published in: Vnitř Lék 2016; 62(Suppl 3): 50-55
Category: Reviews

Overview

The article gives an overview of the circumstances–eating habits, disorders of absorption in the intestinal and other disease, certain drugs and substances occurring in nature affecting the metabolism of thyroid hormones on many levels, thyroid disruptors, for which compensation may be healing broken thyroid function to be unsatisfactory in spite of following the rules of substitution treatment. Knowledge of these conditions and adapting to them timely by adjusting either the eating habits or thyroid hormone by adjusting benefits, allowing the patient to improve his subjective feelings from treatment and improving compliance.

Key words:
absorption – biological availability – compliance – levothyroxine therapy – drug interactions – nutritional habits – thyroid disruptors

Sources

1. Schloot N, Eisenbart GS. Isohormonal therapy of endocrine autoimmunity. Imunol Today 1995; 16(6): 289–294.

2. Šterzl I, Hrdá P. Izohormonální terapie autoimunitních endokrinopatií. Alergie 2010; 14(1): 56–59.

3. Peterson LD, van der Keur M, de Vries RR et al. Autoreactive and immunoregulatory T-cell subsets in insulin-dependent diabetes mellitus. Diabetologia 1999; 42(4): 443–449.

4. Santini F, Pinchera A, Marsili H et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab 2005; 90(1): 124–127.

5. Asvold BO, Bjoro T, Vatten LJ. Association of serum TSH with high body mass differs between smokers and never-smokers. J Clin Endocrinol Metab 2009; 94(12): 5023–5027. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2009–1180>.

6. Weiss RE, Brown RL. Doctor...... could it be my thyroid? Arch Intern Med 2008; 168(6): 568–569. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.168.6.568>.

7. Kok P, Roelfsema F, Langendonk JG et al. High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction. J Clin Endocrinol Metab 2005; 90(8): 4659–4663.

8. Reinehr T, de Sousa G, Andler W. Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. J Clin Endocrinol Metab 2006; 91(8): 3088–3091.

9. Onur S, Haas V, Bosy-Westphal A et al. L-tri-iodothyronine is a major determinant of rating energy expenditure in underweight patiens with anorexia nervosa and during weight gain. Eur J Endocrinol 2005; 152(2): 179–184.

10. Knudsen N, Bulow I, Laurberg P et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab 2005; 90(7): 4019–4024.

11. Jonklaas J. Sex and age differences in levothyroxine dosage requirement. Endocr Pract 2010; 16(1): 71–79. Dostupné z DOI: <http://dx.doi.org/10.4158/EP09257.OR>.

12. Burman KD, Hennessey JV, McDermott M et al. The FDA revises requirements for levothyroxine products. Thyroid 2008; 18(5): 487–490. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2008.0109>.

13. [American Thyroid Association; Endocrine Society; American Association of Clinical Endocrinologists]. Joint statement on the U. S. Food and drug Administration´s decision regarding bioequivalence of levothyroxine sodium. Thyroid 2004; 14(7): 486.

14. Read DG, Hays MT, Hershman JM. Absorption of oral thyroxine in hypothyroid and normal man. J Clin Endocrinol Metab1970; 30(6): 798–799. Dostupné z DOI: <http://dx.doi.org/10.1210/jcem-30–6-798>.

15. Centanni M, Gargano L, Canettieri G et al. Malabsorption of T4: new insights on oral thyroxine treatment. Hot Thyroidology – Official Journal of ETA 2007; n. 169. Dostupné z DOI: http://www.hotthyroidology.com/editorial_169.html.

16. Wenzel KW, Kirschieper HE. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism 1977; 26(1): 1–8.

17. Hanneman G, Docter R, Friesema EC et al. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavaibility. Endocr Rev 2001; 22(4): 451–476.

18. Centanni M, Gargano L, Canettieri G et al. Thyroxine in goiter, Helicobacter pylori infection and chronic gastritis. N Engl J Med 2006; 354(17): 1787–1795.

19. Centanni M, Robbins J. Role of sodium in thyroid hormone uptake by rat skeletal muscle. J Clin Invest 1987; 80(4): 1068–1072.

20. Centanni M, Marignani M, Gargano L et al Atrophic body gastritis in patients with autoimmnune thyroid disease: an underdiagnosed association. Arch Intern Med 1999; 159(15): 1726–1730.

21. Sachs G, Shin JM, Munson K et al. Review: the control of gastric acid and Helicobacter pylori eradication. Aliment Prarmacol Ther 2000; 14(11): 1383–1401.

22. Yao X, Forte JG. Cell biology of acid secretion by the parietal cell. Annu Rev Physiol 2003; 65: 103–131.

23. Lahner E, Annibale B, Delle F. Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pfarmacol Ther 2009; 29(4): 379–386. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2036.2008.03906.x>.

24. Ananthakrishnan S, Braverman LE, Levin RM et al. The effect of famotidine, esomeprazole and ezetimibe on levothyroxine absorption. Thyroid 2008; 18(5): 493–498. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2007.0381>.

25. Collin P, Kaukinen K, Valimaki M et al. Endocrinological disorders and celiac disease. Endocr Rev 2002; 23(4): 464–483.

26. Boelaert K, Newby PR, Simmonds MJ et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med 2010; 123(2): 183.e1–9. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2009.06.030>.

27. Surks MI, Oritz E, Daniels GH et al. Subclinical thyroid disease .Scientific review and qudelines for diagnosis and management. JAMA 2004; 291: 228–238.

28. Mc Dermot JH, Coss A, Walsh CH Celiac disease presenting as resistant hypothyroidism. Thyroid 2005; 15(4): 386–388.

29. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 2010; 11(1): 41–50. Dostupné z DOI: <http://dx.doi.doi.org/10.1111/j.1467–789X.2009.00614.x>.

30. Seppel T, Rose F, Schlaghecke R. Chronic intestinal giardiasis with isolated levothyroxine malabsorption as reason for severe hypothyroidism-implications for localization of thyroid hormone absorption in the gut. Exp Clin Endocrinol Diabetes 1996; 104(2): 180–182.

31. Muňoz-Torres M, Varsavsky M. Lactose intolerance revealed by severe resistence to treatment with levothyroxine. Thyroid 2006; 16(11): 1171–1173.

32. Pantos C, Mourouzis I, Xinaris C et al. Thyroid hormone and myocardial ischaemia. J Stroid Biochem Mol Biol 2008; 109(3–5): 314–322. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jsbmb.2008.03.011>.

33. Sandek A, Rauchhaus M, Anker SD et al. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care 2008; 11(5): 632–639. Dostupné z DOI: <http://dx.doi.org/10.1097/MCO.0b013e32830a4c6e>.

34. Goarin JP, Cohen S, Riou E et al. The effects of triiodothyronine on hemodynamic status and cardiac function in potentional heart donors. Anesth Analg 1996; 83(1): 41–47.

35. Cooper DK, Novitzky D, Wicomb WN et al. A review of studies relating to thyroid hormone therapy in brain-dead organ donors. Front Biosci (Landmark Ed) 2009; 14: 3750–3770.

36. Mullis-Jansson SL, Argenaziano M, Corwin S et al. A ramdomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiovasc Surg 1999; 117(6): 1128–1134.

37. Novitzky D, Cooper DK, Swanepoel A. Ionotropic effect of triiodothyronine (T3) in low cardiac output following cardioplegic arrest and cardiopulmonary bypass: an initial experience in patients undergoing open heart surgery. Eur J Cardiothoracic Surg 1989; 3(2): 140–145.

38. Henderson KK, Danzi S, Paul JT et al. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ Heart Fail 2009; 2(3): 243–252. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.108.810747>.

39. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab 1986; 63(1): 1–8.

40. Moruzzi P, Doria E, Agostoni PG. Medium-term effectiveness of L-thyroxine treatment in idiopatic dilated cardiomyopathy. Am J Med1996; 101(5): 461–467.

41. Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid 2001; 11(10): 967–971.

42. Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23(6): 735–751. Dostupné z DOI: <http://dx.doi.org/10.1016/j.beem.2009.07.001>.

43. Cohen-Lehman J, Dahl P, Danzi S et al. Effects of amiodarone therapy on thyroid fiction. Nat Rev Endocrinol 2010; 6(1): 34–41. Dostupné z DOI: <http://dx.doi.org/10.1038/nrendo.2009.225>.

44. Cappelli C, Rotondi M, Pirola I et al. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid and euthyroid on L-T4 therapy patients. Diabetes Care 2009; 32(9): 1589–1590. Dostupné z DOI: <http://dx.doi.org/10.2337/dc09–0273>.

45. Benvega S, Bartolone L, Pappalardo MA et al. Altered intestinal absorption of L-tyroxine caused by coffe. Thyroid 2008; 18(3): 293–301. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2007.0222>.

46. Lilja JJ, Laitinene K, Neuvonen PJ. Effects of grapefruit juice on the absorption levothyroxine. Br J Clin Pharmacol 2005; 60(3): 337–341.

47. Chiu AC, Sherman SI. Effects of pharmacological fiber supplements on levothyroxine absorption. Thyroid 1998; 8(8): 667–671.

48. Elliot DP. Effect of L-T4 administration time on serum in elderly patients. Ann Pharmacotherapy 2001; 35(5): 529–532.

49. Bolk N, Visser TJ, Kalsbeek A et al. Effects of evening vs morning tyroxine ingestion on serum thyroid hormone profiles in hypothyroid patients. Clin Endocrinol 2007; 66(1): 43–48.

50. Patrick L. Thyroid disruption: mechanism and clinical implications in human health. Altern Med Rev 2009; 14(4): 326–346.

51. Uzma N, Salar BM, Kumar BS et al. Impact of organic solvents an environmental pollutants on the physiological function in petrol filling workers. Int J Environ Res Public Health 2008; 5(3): 139–146.